This article will reveal an in-depth analysis of drugs being developed to combat immunological disorders. Big Pharma is keenly interested in the global immunology drugs market, which is anticipated...

In the most recent trading session, AbbVie (ABBV) closed at $173.70, indicating a +1.37% shift from the previous trading day.

Dividend growth investing is a powerful strategy for building lasting wealth. Companies that consistently raise their dividends tend to possess durable competitive advantages, robust cash flows, an...

If you're a retiree looking for dependable and reliable dividend income, there are many quality stocks out there that can be suitable options for your portfolio. The stocks I've listed below pay ab...

AbbVie, with a market cap of over $300 billion, shows strong cash flow potential despite patent expirations, making it a valuable investment. The company reported strong 3Q financials, with adjuste...

This article will provide an in-depth analysis of drugs being developed to combat cancer. Big Pharma is keenly interested in the global cancer therapeutics market, which is expected to exceed $400 ...

Hormel Foods extends its 52-year dividend streak with a 2.6% increase; the group averages a 5.9% increase, median 5.8%. My strategy focuses on buying, holding, and adding to companies with consiste...

There might not be a better place to find winning stocks that can slowly make you wealthy over decades than the healthcare industry. It's an evergreen, multitrillion-dollar market that promotes gro...

AbbVie (ABBV) shares fell Friday after the biotech firm announced it would take an estimated $3.5 billion impairment charge because of the failure of one of its drugs.

MoneyShow presents top investment ideas for 2025 from their contributors. This year's edition presents a broad mix of theme-based stock picks, momentum-driven high-flyers and beaten-up stocks with ...

AbbVie's Stock Is Unfairly Cheap

AbbVie (ABBV) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

ABBV lowers adjusted earnings guidance for 2024 from $10.90-$10.94 per share to $10.02-$10.06 after incurring $1.6 billion in acquisition expenses in Q4.

AbbVie lowered its 2024 adjusted profit forecast on Monday as the drugmaker incurred $1.6 billion in acquisition expenses related to milestone payments as well as research-and-development costs.

When it comes to dividend investing, there are two basic paths you can take. You could seek out businesses that are raising their payouts at a rapid pace, but these stocks tend to offer low yields.